About AstraZenecaCopy link to section
What is AstraZeneca?Copy link to section
AstraZeneca is a British pharmaceutical company. Headquartered in Cambridge, United Kingdom, and founded in 1999, it now operates in over 100 countries worldwide. It focuses on developing innovative treatments for various diseases, including oncology, cardiovascular, renal, metabolism, respiratory, and immunology.
How does AstraZeneca make money?Copy link to section
AstraZeneca makes money by selling pharmaceutical products, collaborations and partnerships, as well as licensing and royalty agreements. It has several treatments and therapies and became a household name during the pandemic when it was one of the first companies to release a coronavirus vaccine.
What is AstraZeneca’s best selling product?Copy link to section
AstraZeneca’s best selling products are from its oncology department. Tagrisso, which is used to treat non-small cell lung cancer, was its best selling drug in 2022, with sales of $5.4 billion. Another cancer drug, Imfinzi, generated $4.4 billion for the same period. In 2022, AstraZeneca reported total revenue of $29.2 billion, up 6% from the previous year.
Who are the key executives at AstraZeneca?Copy link to section
Pascal Soriot is the current CEO of AstraZeneca, here are a few other members of its leadership team.
- Pascal Soriot D.V.M., M.B.A. CEO & Exec. Director
- Aradhana Sarin M.D. Exec. Director
- Pam P. Cheng. EVP of Operations, IT & Sustainability and Member of External Sustainability Advisory Board
- Andrew P. Barnett. Head of Investor Relations
- Jeffrey Pott. CHRO, Chief Compliance Officer, Gen. Counsel & Member of External Sustainability Advisory Board
- Gonzalo Vina. Head of Global Media Relations
- Menelas Pangalos Ph.D. EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
- Ruud Dobber Ph.D. Exec. Vice-Pres of BioPharmaceuticals Bus. Unit
- Susan Mary Galbraith. M.D., Ph.D. Exec. VP of Oncology R&D
- Leon Wang. Exec. VP of International & China Pres
Where can I buy shares in AstraZeneca?Copy link to section
You can buy AstraZeneca stock on a stock trading platform. These platforms are extremely simple to use but there are different options to suit your specific needs. If you are a first-time investor you might want to use a trading platform for beginners, while if you plan on doing a lot of trading from your phone, a stock trading app might be best.
Are there any other ways to invest in AstraZeneca?Copy link to section
The simplest way to invest in AstraZeneca is to buy shares through a stock broker. However, you can also invest through an ETF or a fund. The best ETFs allow you to invest in the stock market more generally rather than focus on one company.
More about the AZN priceCopy link to section
What is the AstraZeneca stock price today?Copy link to section
The AZN stock price today is currently $68.60 as of 29 March 2023. The price of AstraZeneca is up 5.4% over the past 52 weeks. You can use the live AstraZeneca stock chart to track the NASDAQ:AZN price in real time above, or compare the AstraZeneca value today to its past performance using the AstraZeneca financials tab at the top of this page.
What is the 52-week low for AstraZeneca stock?Copy link to section
The 52-week low for AstraZeneca stock is $52.65. AZN stock is currently 30.11% above the 52-week low.
What is the 52-week high for AstraZeneca stock?Copy link to section
The 52-week high for AstraZeneca stock is $72.12. AZN stock is currently 4.35%] below the 52-week high.
What is the stock forecast for AstraZeneca?Copy link to section
The average AstraZeneca stock forecast has a price target of $78.87 by the end of 2023. AstraZeneca’s latest financial results, the broader economic outlook, and the amount of competition in the industry all influence these forecasts.
It’s best to take analyst forecasts with a grain of salt but you can use their estimates to help you understand the weight of opinion about a stock.
More stock guidesCopy link to section
FAQsCopy link to section
AstraZeneca’s market capitalisation is $212.63 billion. This is calculated by multiplying the number of shares that have been issued by the current AZN share price. Another way of measuring this is enterprise value, which includes AstraZeneca’s debt obligations. AstraZeneca’s enterprise value is $232.62 billion.
AstraZeneca went public via an initial public offering on July 15, 1993. It is listed on the London Stock Exchange and NASDAQ stock exchanges. On its first day of trading, its shares were priced at £5.30 in London and $23.00 in the United States. Its IPO raised over £600 million for the company.
The largest shareholder of AstraZeneca stock is Price (T.Rowe) Associates Inc, which owns 2.61% of the company.
AstraZeneca has several competitors within the pharmaceutical industry. Below you can find a few of its largest competitors.
- Pfizer. Pfizer is a global pharmaceutical company known for its covid vaccine.
- GSK. GSK is a British multinational pharmaceutical company.
- Moderna. Moderna is a young pharmaceutical company
AstraZeneca has had a total of two stock splits in its history. The first was in 1998 and the most recent, a 2-for-1 split in 2015.
AstraZeneca reports earnings four times per year at the end of each quarter. It generally reports in March, June, September, and December. The exact dates it releases its earnings may change and it is recommended to visit its investor relations page for the most up to date information.
Yes, AstraZeneca is a dividend paying company and has a current yield of 2.11%.
Invezz is a place where people can find reliable, unbiased information about finance, trading, and investing – but we do not offer financial advice and users should always carry out their own research. The assets covered on this website, including stocks, cryptocurrencies, and commodities can be highly volatile and new investors often lose money. Success in the financial markets is not guaranteed, and users should never invest more than they can afford to lose. You should consider your own personal circumstances and take the time to explore all your options before making any investment. Read our risk disclaimer >